Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting
| العنوان: | Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting |
|---|---|
| المؤلفون: | Junlong Hu, Minlu Zhang, Hao Liu, Jiaxi Zhu, Rui Wang, Yunpeng Zhu, Qing Xue, Qiang Zhao, Xiaowei Wang |
| المصدر: | The Journal of Thoracic and Cardiovascular Surgery. 163:1030-1039.e4 |
| بيانات النشر: | Elsevier BV, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Male, Pulmonary and Respiratory Medicine, China, Ticagrelor, medicine.medical_specialty, Time Factors, Coronary Artery Disease, 030204 cardiovascular system & hematology, Risk Assessment, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Risk Factors, law, Internal medicine, medicine, Humans, Coronary Artery Bypass, Vascular Patency, Aged, Aspirin, business.industry, Dual Anti-Platelet Therapy, Graft Occlusion, Vascular, Thrombosis, Cholesterol, LDL, Middle Aged, medicine.disease, Regimen, Treatment Outcome, medicine.anatomical_structure, 030228 respiratory system, Cardiology, Female, lipids (amino acids, peptides, and proteins), Surgery, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, Vein graft disease, business, Biomarkers, Platelet Aggregation Inhibitors, Mace, Artery, medicine.drug |
| الوصف: | It remains unclear whether aggressive low-density lipoprotein cholesterol (LDL-C) management (1.8 mmol/L) can slow the process of vein graft stenosis. This study aimed to explore the impact of baseline LDL-C levels on vein graft patency in patients on ticagrelor with or without aspirin 1 year after coronary artery bypass grafting (CABG).This was a post hoc analysis of the DACAB (Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery) trial (NCT02201771), a randomized controlled trial (ticagrelor + aspirin or ticagrelor vs aspirin) of patients undergoing CABG in China. The study subjects were stratified as LDL-low (baseline LDL-C1.8 mmol/L, 148 patients with 430 vein grafts) versus LDL-high (baseline LDL-C ≥1.8 mmol/L, 352 patients with 1030 vein grafts). The primary outcome was the 1-year vein graft patency (Fitzgibbon grade A) assessed by coronary computed tomographic angiography or coronary angiography.Baseline/1-year LDL-C were 1.4/1.6 and 2.6/2.4 mmol/L in the LDL-low and LDL-high subgroups, respectively. Regardless of antiplatelet regimen, no significant inter-subgroup difference was observed for 1-year graft patency (LDL-low: 83.8% [359/430 grafts]; LDL-high: 82.3% [848/1030 grafts]; adjusted OR for non-patency [ORIn general, baseline LDL-C is not associated with 1-year vein graft patency after CABG. Regardless of the baseline LDL-C levels, ticagrelor + aspirin was superior to aspirin alone in maintaining vein graft patency. The primary factor causing early vein graft disease might not be atherosclerosis but thrombosis. |
| تدمد: | 0022-5223 0220-1771 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c5c0662f38e53499c1c55a5ff7e17cfTest https://doi.org/10.1016/j.jtcvs.2020.03.039Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....9c5c0662f38e53499c1c55a5ff7e17cf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00225223 02201771 |
|---|